Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Edith T Zemanick

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PEDS
Phone720/777-6181

    Collapse Research 
    Collapse research activities and funding
    K23HL114883     (ZEMANICK, EDITH TOWLER)Jan 1, 2014 - Dec 31, 2017
    NIH
    Airway Microbiome in Cystic Fibrosis Pulmonary Exacerbations
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sanders DB, Bartz TM, Zemanick ET, Hoppe JE, Hinckley Stukovsky KD, Cogen JD, Bendy L, McNamara S, Enright E, Kime NA, Kronmal RA, Edwards TC, Morgan WJ, Rosenfeld M. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies. Ann Am Thorac Soc. 2023 12; 20(12):1769-1776. PMID: 37683122.
      View in: PubMed
    2. Graham BIM, Harris JK, Zemanick ET, Wagner BD. Integrating airway microbiome and blood proteomics data to identify multi-omic networks associated with response to pulmonary infection. Microbe. 2023 Dec; 1. PMID: 38264413.
      View in: PubMed
    3. Miller JE, Liu CM, Zemanick ET, Woods JC, Goss CH, Taylor-Cousar JL, Beswick DM. Olfactory loss in people with cystic fibrosis: Community perceptions and impact. J Cyst Fibros. 2023 Nov 17. PMID: 37981480.
      View in: PubMed
    4. Wagner BD, Zemanick ET, Sagel SD, Robertson CE, Stevens MJ, Mayer-Hamblett N, Retsch-Bogart G, Ramsey BW, Harris JK. Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection. BMC Microbiol. 2023 10 27; 23(1):312. PMID: 37891457.
      View in: PubMed
    5. Mayer-Hamblett N, Clancy JP, Jain R, Donaldson SH, Fajac I, Goss CH, Polineni D, Ratjen F, Quon BS, Zemanick ET, Bell SC, Davies JC, Jain M, Konstan MW, Kerper NR, LaRosa T, Mall MA, McKone E, Pearson K, Pilewski JM, Quittell L, Rayment JH, Rowe SM, Taylor-Cousar JL, Retsch-Bogart G, Downey DG. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective. Lancet Respir Med. 2023 Oct; 11(10):932-944. PMID: 37699421.
      View in: PubMed
    6. Poore TS, Zemanick ET. Infection, Allergy, and Inflammation: The Role of Aspergillus fumigatus in Cystic Fibrosis. Microorganisms. 2023 Aug 05; 11(8). PMID: 37630573.
      View in: PubMed
    7. Harris JK, Wagner BD, Robertson CE, Stevens MJ, Lingard C, Borowitz D, Leung DH, Heltshe SL, Ramsey BW, Zemanick ET. Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screen. J Cyst Fibros. 2023 07; 22(4):644-651. PMID: 37137746.
      View in: PubMed
    8. VanDevanter DR, Zemanick ET, Konstan MW, Ren CL, Odem-Davis K, Emerman I, Young J, Mayer-Hamblett N. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials. J Cyst Fibros. 2023 07; 22(4):652-655. PMID: 37100705.
      View in: PubMed
    9. Gifford AH, Hinton AC, Jia S, Nasr SZ, Mermis JD, Lahiri T, Zemanick ET, Teneback CC, Flume PA, DiMango EA, Sadeghi H, Polineni D, Dezube RH, West NE, Dasenbrook EC, Lucas FL, Zuckerman JB. Complications and Practice Variation in the Use of Peripherally Inserted Central Venous Catheters in People With Cystic Fibrosis: The Prospective Study of Peripherally Inserted Venous Catheters in People With Cystic Fibrosis Study. Chest. 2023 09; 164(3):614-624. PMID: 37019356.
      View in: PubMed
    10. Jordan KD, Zemanick ET, Taylor-Cousar JL, Hoppe JE. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy. Expert Rev Respir Med. 2023 02; 17(2):97-108. PMID: 36803356.
      View in: PubMed
    11. Hahn A, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Crandall KA, Zemanick ET. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis. Sci Rep. 2023 01 21; 13(1):1217. PMID: 36681756.
      View in: PubMed
    12. Shumyatsky G, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Crandall KA, Zemanick ET, Hahn A. Using metabolic potential within the airway microbiome as predictors of clinical state in persons with cystic fibrosis. Front Med (Lausanne). 2022; 9:1082125. PMID: 36698799.
      View in: PubMed
    13. Hoppe JE, Zemanick ET, Martiniano SL. Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing. Am J Respir Crit Care Med. 2022 Dec 01; 206(11):1308-1310. PMID: 35947636.
      View in: PubMed
    14. Inam Z, Felton E, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Zemanick ET, Crandall KA, Hahn A. Impact of Antibiotics on the Lung Microbiome and Lung Function in Children With Cystic Fibrosis 1 Year After Hospitalization for an Initial Pulmonary Exacerbation. Open Forum Infect Dis. 2022 Sep; 9(9):ofac466. PMID: 36168550.
      View in: PubMed
    15. Mayer-Hamblett N, Zemanick ET, Odem-Davis K, VanDevanter D, Warden M, Rowe SM, Young J, Konstan MW. Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study. J Cyst Fibros. 2023 01; 22(1):79-88. PMID: 35871974.
      View in: PubMed
    16. Rice JD, Johnson RL, Juarez-Colunga E, Zemanick ET, Rosenfeld M, Wagner BD. Application of gap time analysis with flexible hazards to pulmonary exacerbations in the EPIC observational study. Biom J. 2022 08; 64(6):1075-1089. PMID: 35434808.
      View in: PubMed
    17. Broderick DTJ, Waite DW, Marsh RL, Camargo CA, Cardenas P, Chang AB, Cookson WOC, Cuthbertson L, Dai W, Everard ML, Gervaix A, Harris JK, Hasegawa K, Hoffman LR, Hong SJ, Josset L, Kelly MS, Kim BS, Kong Y, Li SC, Mansbach JM, Mejias A, O'Toole GA, Paalanen L, P?rez-Losada M, Pettigrew MM, Pichon M, Ramilo O, Ruokolainen L, Sakwinska O, Seed PC, van der Gast CJ, Wagner BD, Yi H, Zemanick ET, Zheng Y, Pillarisetti N, Taylor MW. Bacterial Signatures of Paediatric Respiratory Disease: An Individual Participant Data Meta-Analysis. Front Microbiol. 2021; 12:711134. PMID: 35002989.
      View in: PubMed
    18. Poore TS, Meier M, Towler E, Martiniano SL, Brinton JT, DeBoer EM, Sagel SD, Wagner BD, Zemanick ET. Clinical characteristics of people with cystic fibrosis and frequent fungal infection. Pediatr Pulmonol. 2022 01; 57(1):152-161. PMID: 34687280.
      View in: PubMed
    19. Bozzella MJ, Chaney H, Sami I, Koumbourlis A, Bost JE, Zemanick ET, Freishtat RJ, Crandall KA, Hahn A. Impact of Anaerobic Antibacterial Spectrum on Cystic Fibrosis Airway Microbiome Diversity and Pulmonary Function. Pediatr Infect Dis J. 2021 11 01; 40(11):962-968. PMID: 34269323.
      View in: PubMed
    20. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 06 15; 203(12):1522-1532. PMID: 33734030.
      View in: PubMed
    21. Poore TS, Taylor-Cousar JL, Zemanick ET. Cardiovascular complications in cystic fibrosis: A review of the literature. J Cyst Fibros. 2022 01; 21(1):18-25. PMID: 34140249.
      View in: PubMed
    22. Hahn A, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Zemanick ET, Louie S, Crandall KA. Importance of beta-lactam pharmacokinetics and pharmacodynamics on the recovery of microbial diversity in the airway of persons with cystic fibrosis. J Investig Med. 2021 10; 69(7):1350-1359. PMID: 34021052.
      View in: PubMed
    23. Poore TS, Hong G, Zemanick ET. Fungal Infection and Inflammation in Cystic Fibrosis. Pathogens. 2021 May 18; 10(5). PMID: 34069863.
      View in: PubMed
    24. Lenhart-Pendergrass PM, Anthony M, Sariyska S, Andrews A, Scavezze H, Towler E, Martiniano SL, Hoppe JE, Zemanick ET. Detection of bacterial pathogens using home oropharyngeal swab collection in children with cystic fibrosis. Pediatr Pulmonol. 2021 07; 56(7):2043-2047. PMID: 33847465.
      View in: PubMed
    25. Khalaf RT, Furuta GT, Wagner BD, Robertson CE, Andrews R, Stevens MJ, Fillon SA, Zemanick ET, Harris JK. Influence of Acid Blockade on the Aerodigestive Tract Microbiome in Children With Cystic Fibrosis. J Pediatr Gastroenterol Nutr. 2021 04 01; 72(4):520-527. PMID: 33394582.
      View in: PubMed
    26. Wagner BD, Berkalieva A, Borges M, Fleming G, Graham N, Peterson E, Jin X, Zemanick ET. Change in circulating proteins during treatment of pulmonary exacerbation in patients with cystic fibrosis. Health Sci Rep. 2021 Mar; 4(1):e246. PMID: 33614983.
      View in: PubMed
    27. Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J Cyst Fibros. 2021 11; 20(6):965-971. PMID: 33573995.
      View in: PubMed
    28. Drake MG, Shah NG, Lee M, Brady A, Connors GR, Clark BJ, Kritek PA, McCallister JW, Burkart KM, Pedraza I, Jamieson D, Ingram JL, Lynch L, Makani SS, Siegel-Gasiewski J, Larsson EM, Zemanick ET, Liptzin DR, Good R, Crotty Alexander LE. Development of a National Academic Boot Camp to Improve Fellowship Readiness. ATS Sch. 2020 Dec 22; 2(1):49-65. PMID: 33870323.
      View in: PubMed
    29. Hoppe JE, Hinds DM, Colborg A, Wagner BD, Morgan WJ, Rosenfeld M, Zemanick ET, Sanders DB. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers. Pediatr Pulmonol. 2020 12; 55(12):3400-3406. PMID: 32970375.
      View in: PubMed
    30. Hahn A, Burrell A, Ansusinha E, Peng D, Chaney H, Sami I, Perez GF, Koumbourlis AC, McCarter R, Freishtat RJ, Crandall KA, Zemanick ET. Airway microbial diversity is decreased in young children with cystic fibrosis compared to healthy controls but improved with CFTR modulation. Heliyon. 2020 Jun; 6(6):e04104. PMID: 32514485.
      View in: PubMed
    31. Jewell MP, Saccomano SC, David AA, Harris JK, Zemanick ET, Cash KJ. Nanodiagnostics to monitor biofilm oxygen metabolism for antibiotic susceptibility testing. Analyst. 2020 Jun 07; 145(11):3996-4003. PMID: 32342070.
      View in: PubMed
    32. Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, Rowe SM, Sagel SD. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Ann Am Thorac Soc. 2020 02; 17(2):212-220. PMID: 31604026.
      View in: PubMed
    33. Martiniano SL, Esther CR, Haworth CS, Kasperbauer SH, Zemanick ET, Caverly LJ. Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis. Pediatr Pulmonol. 2020 02; 55(2):521-525. PMID: 31821718.
      View in: PubMed
    34. Hahn A, Zemanick ET. Bacterial Community Variability: Outliers May Be Leading Us Astray. Ann Am Thorac Soc. 2019 12; 16(12):1499-1501. PMID: 31774321.
      View in: PubMed
    35. Zemanick ET, Bell SC. Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis. Curr Opin Pulm Med. 2019 11; 25(6):636-645. PMID: 31397692.
      View in: PubMed
    36. Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA. Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 05; 19(3):370-375. PMID: 31680041.
      View in: PubMed
    37. Zemanick ET, Accurso FJ. Entering the era of highly effective CFTR modulator therapy. Lancet. 2019 11 23; 394(10212):1886-1888. PMID: 31679947.
      View in: PubMed
    38. Jewell MP, Galyean AA, Kirk Harris J, Zemanick ET, Cash KJ. Luminescent Nanosensors for Ratiometric Monitoring of Three-Dimensional Oxygen Gradients in Laboratory and Clinical Pseudomonas aeruginosa Biofilms. Appl Environ Microbiol. 2019 10 15; 85(20). PMID: 31420335.
      View in: PubMed
    39. Theprungsirikul J, Skopelja-Gardner S, Meagher RE, Clancy JP, Zemanick ET, Ashare A, Rigby WFC. Dissociation of systemic and mucosal autoimmunity in cystic fibrosis. J Cyst Fibros. 2020 03; 19(2):196-202. PMID: 31262645.
      View in: PubMed
    40. Martiniano SL, Daines CL, Dellon EP, Esther CR, Muhlebach MS, Ong T, Rabinowitz EC, Toprak D, Zemanick ET. Highlights from the 2018 North American cystic fibrosis conference. Pediatr Pulmonol. 2019 07; 54(7):941-948. PMID: 31091021.
      View in: PubMed
    41. Zemanick ET, Polineni D. Unraveling the CFTR Function-Phenotype Connection for Precision Treatment in Cystic Fibrosis. Am J Respir Crit Care Med. 2019 May 01; 199(9):1053-1054. PMID: 30939246.
      View in: PubMed
    42. Hahn A, Fanous H, Jensen C, Chaney H, Sami I, Perez GF, Koumbourlis AC, Louie S, Bost JE, van den Anker JN, Freishtat RJ, Zemanick ET, Crandall KA. Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis. Sci Rep. 2019 02 22; 9(1):2534. PMID: 30796252.
      View in: PubMed
    43. Juarez-Colunga E, Rosenfeld M, Zemanick ET, Wagner B. Application of multiple event analysis as an alternative approach to studying pulmonary exacerbations as an outcome measure. J Cyst Fibros. 2020 01; 19(1):114-118. PMID: 30642785.
      View in: PubMed
    44. DeBoer EM, Wagner BD, Popler J, Harris JK, Zemanick ET, Accurso FJ, Sagel SD, Deterding RR. Novel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid. Proteomics Clin Appl. 2019 05; 13(3):e1800085. PMID: 30431231.
      View in: PubMed
    45. Li A, Vigers T, Pyle L, Zemanick E, Nadeau K, Sagel SD, Chan CL. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. J Cyst Fibros. 2019 01; 18(1):144-149. PMID: 30104123.
      View in: PubMed
    46. Hoppe JE, Wagner BD, Accurso FJ, Zemanick ET, Sagel SD. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. 2018 11; 17(6):760-768. PMID: 29921503.
      View in: PubMed
    47. Wagner BD, Grunwald GK, Zerbe GO, Mikulich-Gilbertson SK, Robertson CE, Zemanick ET, Harris JK. On the Use of Diversity Measures in Longitudinal Sequencing Studies of Microbial Communities. Front Microbiol. 2018; 9:1037. PMID: 29872428.
      View in: PubMed
    48. Martiniano SL, Toprak D, Ong T, Zemanick ET, Daines CL, Muhlebach MS, Esther CR, Dellon EP. Highlights from the 2017 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2018 07; 53(7):979-986. PMID: 29660839.
      View in: PubMed
    49. Nasir M, Bean HD, Smolinska A, Rees CA, Zemanick ET, Hill JE. Volatile molecules from bronchoalveolar lavage fluid can 'rule-in' Pseudomonas aeruginosa and 'rule-out' Staphylococcus aureus infections in cystic fibrosis patients. Sci Rep. 2018 01 16; 8(1):826. PMID: 29339749.
      View in: PubMed
    50. Hoppe JE, Wagner BD, Sagel SD, Accurso FJ, Zemanick ET. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis. BMC Pulm Med. 2017 Dec 11; 17(1):188. PMID: 29228933.
      View in: PubMed
    51. Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J. 2017 11; 50(5). PMID: 29146601.
      View in: PubMed
    52. Zemanick ET, Daines CL, Dellon EP, Esther CR, Kinghorn B, Ong T, Muhlebach MS. Highlights from the 2016 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2017 08; 52(8):1103-1110. PMID: 28696526.
      View in: PubMed
    53. Williamson KM, Wagner BD, Robertson CE, Johnson EJ, Zemanick ET, Harris JK. Impact of enzymatic digestion on bacterial community composition in CF airway samples. PeerJ. 2017; 5:e3362. PMID: 28584706.
      View in: PubMed
    54. Hoppe JE, Zemanick ET. Lessons from the lower airway microbiome in early CF. Thorax. 2017 12; 72(12):1063-1064. PMID: 28450530.
      View in: PubMed
    55. Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379. PMID: 28209466.
      View in: PubMed
    56. Laguna TA, Wagner BD, Williams CB, Stevens MJ, Robertson CE, Welchlin CW, Moen CE, Zemanick ET, Harris JK. Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis. PLoS One. 2016; 11(12):e0167649. PMID: 27930727.
      View in: PubMed
    57. Muhlebach MS, Beckett V, Popowitch E, Miller MB, Baines A, Mayer-Hamblett N, Zemanick ET, Hoover WC, VanDalfsen JM, Campbell P, Goss CH. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax. 2017 Apr; 72(4):318-326. PMID: 27852955.
      View in: PubMed
    58. Zemanick ET, Hoffman LR. Cystic Fibrosis: Microbiology and Host Response. Pediatr Clin North Am. 2016 08; 63(4):617-36. PMID: 27469179.
      View in: PubMed
    59. Martiniano SL, Sagel SD, Zemanick ET. Cystic fibrosis: a model system for precision medicine. Curr Opin Pediatr. 2016 06; 28(3):312-7. PMID: 27031658.
      View in: PubMed
    60. Zemanick ET, Ong T, Daines CL, Dellon EP, Muhlebach MS, Esther CR. Highlights from the 2015 North American Cystic Fibrosis Conference. Pediatr Pulmonol. 2016 Jun; 51(6):650-7. PMID: 27074261.
      View in: PubMed
    61. Lahiri T, Hempstead SE, Brady C, Cannon CL, Clark K, Condren ME, Guill MF, Guillerman RP, Leone CG, Maguiness K, Monchil L, Powers SW, Rosenfeld M, Schwarzenberg SJ, Tompkins CL, Zemanick ET, Davis SD. Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics. 2016 Apr; 137(4). PMID: 27009033.
      View in: PubMed
    62. Zemanick ET, Wainwright C. Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects. Am J Respir Crit Care Med. 2016 Mar 01; 193(5):473-4. PMID: 26930426.
      View in: PubMed
    63. Johnson EJ, Zemanick ET, Accurso FJ, Wagner BD, Robertson CE, Harris JK. Molecular Identification of Staphylococcus aureus in Airway Samples from Children with Cystic Fibrosis. PLoS One. 2016; 11(1):e0147643. PMID: 26808658.
      View in: PubMed
    64. Zemanick ET, Laguna TA. Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success? Clin Infect Dis. 2015 Sep 01; 61(5):716-8. PMID: 25972023.
      View in: PubMed
    65. Ma DC, Yoon AJ, Faull KF, Desharnais R, Zemanick ET, Porter E. Cholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients. PLoS One. 2015; 10(4):e0125326. PMID: 25919295.
      View in: PubMed
    66. Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, Sokol RJ, Zemanick E, Accurso F, Hoffenberg EJ, Narkewicz MR. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One. 2015; 10(2):e0116967. PMID: 25658710.
      View in: PubMed
    67. Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, Szefler SJ, Accurso FJ, Sagel SD, Harris JK. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc. 2015 Feb; 12(2):221-9. PMID: 25474078.
      View in: PubMed
    68. Hoppe JE, Towler E, Wagner BD, Accurso FJ, Sagel SD, Zemanick ET. Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatr Pulmonol. 2015 Jul; 50(7):638-46. PMID: 25565628.
      View in: PubMed
    69. Zemanick ET, Hoffman L, Rosenfeld M. Narrowing in on early cystic fibrosis lung disease. Am J Respir Crit Care Med. 2014 Nov 15; 190(10):1082-4. PMID: 25398104.
      View in: PubMed
    70. Martiniano SL, Hoppe JE, Sagel SD, Zemanick ET. Advances in the diagnosis and treatment of cystic fibrosis. Adv Pediatr. 2014 Aug; 61(1):225-43. PMID: 25037130.
      View in: PubMed
    71. Zemanick ET, Accurso FJ. Cystic fibrosis transmembrane conductance regulator and pseudomonas. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):763-5. PMID: 24684355.
      View in: PubMed
    72. Zemanick ET, Emerson J, Thompson V, McNamara S, Morgan W, Gibson RL, Rosenfeld M. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol. 2015 Jan; 50(1):42-8. PMID: 24644274.
      View in: PubMed
    73. Harris JK, Zemanick ET. Microbes in bronchiectasis: the forest or the trees? Am J Respir Crit Care Med. 2013 May 15; 187(10):1044-5. PMID: 23675713.
      View in: PubMed
    74. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One. 2013; 8(4):e62917. PMID: 23646159.
      View in: PubMed
    75. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2012 Nov 01; 186(9):857-65. PMID: 22904182.
      View in: PubMed
    76. Wagener JS, Zemanick ET, Sontag MK. Newborn screening for cystic fibrosis. Curr Opin Pediatr. 2012 Jun; 24(3):329-35. PMID: 22491493.
      View in: PubMed
    77. Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr. 2011 Jun; 23(3):319-24. PMID: 21494150.
      View in: PubMed
    78. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, Harris JK. Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens. PLoS One. 2010 Nov 30; 5(11):e15101. PMID: 21152087.
      View in: PubMed
    79. Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol. 2010 Jun; 45(6):569-77. PMID: 20503282.
      View in: PubMed
    80. Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, Retsch-Bogart G, Saiman L, Accurso FJ. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros. 2010 Jan; 9(1):1-16. PMID: 19833563.
      View in: PubMed
    81. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A. 2007 Dec 18; 104(51):20529-33. PMID: 18077362.
      View in: PubMed
    Zemanick's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)